US FDA grants EUA to AstraZeneca’s Evusheld in US for pre-exposure prophylaxis of COVID-19
Phase-III data showed at least six months of protection with one dose in high-risk participant population
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Research
CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
Actemra/RoActemra reduced the risk of death in patients with severe COVID-19, as evidenced by a review of four phase-III studies.…
Amgen announces positive top-line results from Otezla phase-III Discreet study in moderate-to-severe…
Otezla resulted in clinically and statistically significant improvements in measures of genital psoriasis at week 16 compared with…
Moderna COVID vaccine highly effective five months after second dose: Study
Funded by Moderna, the study included 352,878 recipients of two doses of the vaccine matched to 352,878 unvaccinated individuals…
Antibody drug works against COVID-19 Omicron variant: GSK
In a statement, the British drugmaker said that lab tests and a study on hamsters have demonstrated the Sotrovimab antibody…
Emmes completes third ACTT clinical trial for COVID
The ACTT-III trial assessed the efficacy and safety of interferon beta-1a plus Remdesivir compared to Remdesivir alone in…
ITC starts clinical trials of nasal spray for COVID-19 prevention
Developed by scientists at ITC Life Sciences and Technology Centre (LSTC), Bengaluru, the company plans to market the nasal spray…
US FDA approves Takeda’s Livtencity to treat people with post-transplant Cytomegalovirus infection
In the phase-III Solstice study, more than twice the proportion of adult transplant recipients with refractory or resistant (R/R)…
Covaxin shows 50 per cent effectiveness against symptomatic COVID in real-world assessment: Lancet…
The latest study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi, from 15th April…
Gilead submits Biologics Licence Application to USFDA for Bulevirtide
If approved, Bulevirtide will be the first treatment option for adult patients in the US with chronic Hepatitis Delta Virus…
New analyses of two AZD7442 COVID-19 phase-III trials in high-risk populations confirm robust…
Six months' follow-up of prevention trial showed 83 per cent reduced risk of symptomatic COVID-19, with no severe disease or…
NII says Covaxin has cellular immune memory to COVID for at least six months
Immunological memory is the ability of the immune system to respond more rapidly and effectively to pathogens that have been…
Bharat Biotech MD says Ideal time for COVID booster shot is six months after second dose
Taking the Covaxin vaccine by Prime Minister Narendra Modi showed confidence in Indian Science, he said during a summit
Key differences in gut bacterial compositions between Indian and Western populations due to…
In the gut metagenome study from India, the research team from IISER Bhopal studied the bacterial profile of 200 gut samples taken…
Researchers from Tel Aviv University develop process that could reverse early signs of…
The new non-drug method holds promise for preventative therapies
New protein-based COVID vaccine doesn’t need cold storage: Study
The new vaccine design, described in the PNAS journal, could help fill global vaccination gaps and could be applied to vaccines…
Gilead and Merck initiate phase-II study on Lenacapavir and Islatravir oral combo for HIV-1…
This clinical study is the first from Merck and Gilead’s collaboration to develop potential long-acting HIV treatment options
Bausch and Clearside Biomedical announce FDA approval of Xipere
Xipere is the first and only medicine to be approved in the US for delivery via suprachoroidal injection, a method designed to…
FDA approves Roche’s Susvimo for neovascular or “wet” age-related macular degeneration (nAMD)
Susvimo, previously called Port Delivery System with ranibizumab, is the first nAMD treatment in 15 years to provide an…
Pfizer-BioNTech phase-III trial data shows high efficacy of a booster dose of their COVID-19 vaccine
First results from any randomised, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6 per…